Literature DB >> 9532585

Multiple sclerosis: IL-2 and sIL-2R levels in cerebrospinal fluid and serum. Review of literature and critical analysis of ELISA pitfalls.

S Sivieri1, A M Ferrarini, P Gallo.   

Abstract

The presence of interleukin-2 (IL-2) and soluble IL-2 receptors (sIL-2R) in the serum and cerebrospinal fluid (CSF) of patients suffering from multiple sclerosis (MS) has been extensively investigated. These studies, however, have produced conflicting results. The only significant finding concerns the frequent detection of increased sIL-2R levels in the serum in patients with relapsing-remitting MS (RRMS), especially after a short interval of time from the last relapse. Whether this finding can be used for clinical purposes requires further investigation. A standardization of the ELISA methods used to detect cytokines in biological fluids is urgently needed. Increased serum and/or CSF levels of IL-2 and sIL-2R strongly confirm a CD4+ Th1 activation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9532585     DOI: 10.1177/135245859800400103

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  4 in total

1.  Beneficial effect of co-polymer 1 on cytokine production by CD4 T cells in multiple sclerosis.

Authors:  B Fellay; M Chofflon; C Juillard; A M Paunier; T Landis; S Roth; M L Gougeon
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

2.  Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.

Authors:  Y Zhang; M McClellan; L Efros; D Shi; B Bielekova; M T Tang; V Vexler; J P Sheridan
Journal:  Mult Scler       Date:  2013-07-11       Impact factor: 6.312

3.  Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis.

Authors:  Michael J Koziolek; Desiree Tampe; Matthias Bähr; Hassan Dihazi; Klaus Jung; Dirk Fitzner; Reinhard Klingel; Gerhard A Müller; Bernd Kitze
Journal:  J Neuroinflammation       Date:  2012-04-26       Impact factor: 8.322

Review 4.  Herpesviruses--a rationale for antiviral treatment in multiple sclerosis.

Authors:  T Bergström
Journal:  Antiviral Res       Date:  1999-02       Impact factor: 5.970

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.